Assembly Biosciences Receives Bullish Analyst Backing with $38 Price Target
Published on 09/26/2025 at 08:00 | Redaktion boerse-global.de
A significant vote of confidence has emerged for Assembly Biosciences, with JMP Securities initiating coverage of the biopharmaceutical company. The firm assigned a “Market Outperform” rating and set a price target of $38, suggesting substantial upside potential from the stock’s current trading level.
The optimistic outlook from analysts is supported by the company’s robust clinical progress. Key developments in its pipeline are generating considerable interest:
* Promising Herpes Treatment: Interim results from a Phase 1b study for ABI-5366, a potential therapy for recurrent genital herpes, have shown positive outcomes.
* Advancements in Hepatitis B: Encouraging study data has been reported for ABI-4334, which is being developed for chronic Hepatitis B, demonstrating potent antiviral activity.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
